Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks
Procollagen type I N-propeptide is a predictor of skeletal morbidity in patients with malignant osteolytic bone disease on bisphosphonates
Journal
Cancer chemotherapy and pharmacology
Volume
67
Number
5
Pages / Article-Number
1137-44
Keywords
N-telopeptide, Malignant bone disease, Pamidronate, Cancer pain, Bone turnover marker
Abstract
There is an urgent need for individualized treatment of malignant bone disease (MBD), as the clinical benefit from bone-targeted therapies is moderate. We assessed the predictive value of the bone formation marker procollagen type I N-propeptide (PINP) for skeletal morbidity in patients with MBD receiving pamidronate.
